Hemophilia patients in Ireland on clotting factors to be switched to Sobi's extended half-life therapies

The Republic of Ireland has become the first country in Europe where every person with hemophilia will have access to the newest generation of hemophilia treatments, extended half-life therapies, under new supply contracts signed between the HSE (Health Services Executive) and Nordic drugmaker Swedish Orphan Biovitrum (STO: SOBI).

A new contract for the supply of Elocta (efmoroctocog alfa), for the treatment of hemophilia A was signed in January 2018. It follows an earlier contract for the supply of Alprolix (eftrenonacog alfa), for the treatment of hemophilia B. Both Elocta and Alprolix are extended half-life treatments approved for all age groups in the European Union. The Fc-fusion molecule is utilising a natural recycling pathway in the body and the safety profiles of the products are supported by post marketing experience from thousands of patients and during a period of more than three years.

With both of these two-year contracts, Ireland becomes the first country in Europe to switch an entire population undergoing treatment from conventional short-acting therapies to extended half-life therapies for haemophilia A and B.